A study to improve the treatment in the first-line treatment of advanced stage Hodgkin lymphoma
- Conditions
- Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphomaMedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2014-005130-55-AT
- Lead Sponsor
- niversity of Cologne
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 1585
Histologically proven classical Hodgkin lymphoma
First diagnosis, no previous treatment
Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV
Randomized main study: 18 to 60 years of age
Cohort of older patients: 61 to 75 yeras of age
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1500
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 85
Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma
Previous malignancy (exceptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma TNMpT1)
Prior chemotherapy or radiotherapy
Concurrent disease which precludes protocol treatment
Pregnancy, lactation
Non-Compliance
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method